People: NeoStem Inc (NBS)
NBS on American Stock Exchange
0.59USD
24 May 2013
0.59USD
24 May 2013
Price Change (% chg)
$0.02 (+3.51%)
$0.02 (+3.51%)
Prev Close
$0.57
$0.57
Open
$0.58
$0.58
Day's High
$0.59
$0.59
Day's Low
$0.56
$0.56
Volume
619,919
619,919
Avg. Vol
1,103,528
1,103,528
52-wk High
$0.84
$0.84
52-wk Low
$0.37
$0.37
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Robin Smith |
48 | 2006 | Chairman of the Board, Chief Executive Officer |
Lawrence May |
63 | 2006 | Chief Financial Officer, Vice President |
Robert Preti |
56 | 2011 | President and Chief Scientific Officer - PCT |
Joseph Talamo |
43 | 2011 | Vice President, Chief Accounting Officer, Corporate Controller |
Catherine Vaczy |
51 | 2005 | Vice President, General Counsel |
Andrew Pecora |
55 | 2011 | Chief Medical Officer, Director |
Eric Wei |
56 | 2009 | Director |
Richard Berman |
70 | 2006 | Independent Director |
Drew Bernstein |
56 | 2009 | Independent Director |
Martyn Greenacre |
71 | 2011 | Independent Director |
Steven Myers |
66 | 2006 | Independent Director |
Stephen Potter |
56 | 2013 | Independent Director |
Biographies
| Name | Description |
|---|---|
Robin Smith |
Dr. Robin L. Smith is Chairman of the Board, Chief Executive Officer of NeoStem Inc. She joined the Company as Chairman of the Advisory Board in September 2005 and, effective June 2, 2006, became the Chief Executive Officer and Chairman of the Board. Dr. Smith, who received a medical degree from Yale University in 1992 and a master’s degree in business administration from the Wharton School in 1997, brings to experience in medical enterprises and business development. From 2000 to 2003, Dr. Smith served as President & Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare. During her term, the company was selected as being one of the 10 fastest growing technology companies in Houston, Texas. IP2M was sold to a publicly traded company in February 2003. Previously, from 1998 to 2000, Dr. Smith was Executive Vice President and Chief Medical Officer for HealthHelp, Inc., a national radiology management company that managed 14 percent of all healthcare dollars spent by insurance companies. Dr. Smith has acted as a senior advisor to, and investor in, both publicly traded and privately held companies where she has played a role in restructuring and or growing such businesses. She serves on the Board of Trustees of the NYU Langone Medical Center and is past Chairman of the Board of Directors for the New York University Hospital for Joint Diseases where she headed up new development efforts and board member recruitment. Dr. Smith has served on the Board of Choose Living as well as other public and private companies. Currently, Dr. Smith is the President and serves as Chairman of the Board of Directors of The Stem for Life Foundation, a non-profit entity with the goal of educating the public about the growing benefits of stem cell therapies and applications. |
Lawrence May |
Mr. Lawrence A. May is Chief Financial Officer, Vice President of NeoStem Inc. Mr. May, the former Treasurer of Amgen (NASDAQ GS: AMGN), one of the world's biotechnology companies, initially joined the Company to assist with licensing activities in September 2003. He became an officer upon the acquisition of the business of NS California in January 2006. For the last 25 years, Mr. May has worked in the areas of life science and biotechnology. From 1983 to 1998, Mr. May worked for Amgen as Corporate Controller (1983 to 1988), Vice President/Corporate Controller/Chief Accounting Officer (1988 to 1997), and Vice President/Treasurer (1997 to 1998). At Amgen, Mr. May helped build Amgen's accounting, finance and IT organizations. From 1998 to 2000, Mr. May served as the Senior Vice President, Finance & Chief Financial Officer of Biosource International, Inc., a provider of biologic research reagents and assays. From 2000 to May 2003, Mr. May served as the Chief Financial Officer of Saronyx, Inc., a company focused on developing productivity tools and secure communication systems for research scientists. From August 2003 to January 2005, Mr. May served as the Chief Financial Officer of NS California. In March 2005, Mr. May was appointed CEO of NS California and in May 2005 he was elected to the Board of Directors of NS California. He received a Bachelor of Science degree in Business Administration & Accounting in 1971 from the University of Missouri. |
Robert Preti |
Dr. Robert A. Preti is President and Chief Scientific Officer - PCT of NeoStem Inc. Dr. Preti was Scientific Director of Hackensack University Medical Center's stem cell laboratory from 1996 - 1999. Prior to that, he served as director at the Clinical Services Division of the New York Blood Center from 1989 to 1996. He is one of the country's authorities on cell engineering and the principal investigator for a number of clinical trials relating to stem cell transplantation. He was a founding member and Treasurer of the International Society for Hematotherapy and Graft Engineering and served for 10 years on its Executive Committee and Board of Directors. He is now representing Cellular Therapy as a Director of the American Association of Blood Banks. Dr. Preti has authored numerous papers in the field and has been invited to speak at national and international meetings relating to the manufacturing, regulatory and quality aspects of cell therapy and regenerative medicine. In addition to having served as an inspector for the Foundation for Accreditation of Cellular Therapy, Dr. Preti serves on professional and state committees charged with the development of regulations for cellular therapy. Dr. Preti received his Doctor of Philosophy degree from New York University, graduating with distinction. During his tenure at NYU, Dr. Preti studied and received his degrees in Cellular Biology, with a specialty in hematology, studying erythropoiesis under the mentorship of Albert S. Gordon, PhD. Immediately following his graduate work, Dr. Preti joined Marrow Tech, Inc. (which later became Advanced Tissue Sciences) where he served as Group Leader in the development Marrow Tech's proprietary three-dimensional, matrix-based hematopoietic culture system for ex vivo expansion of bone marrow stem cells. |
Joseph Talamo |
Mr. Joseph Talamo is Vice President, Chief Accounting Officer, Corporate Controller of NeoStem Inc., since June 29, 2011. He has been NeoStem's Vice President, Corporate Controller and Chief Accounting Officer since June 2011. From 1996 to 2010, Mr. Talamo held various senior positions at OSI Pharmaceuticals, Inc. (“OSI”), a publicly-traded biopharmaceutical company focused on discovering, developing and commercializing products for the treatment of cancer, diabetes and obesity, and most recently served as its Vice President and Corporate Controller from 2006 to 2010 and its Corporate Controller from 2002 to 2006. While at OSI, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva®, OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group, and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo serves as Treasurer of the Stem For Life Foundation, since 2012. Mr. Talamo served as Treasurer of the OSI Pharmaceuticals Foundation from 2008 to 2010. Mr. Talamo received a Bachelor of Business Administration in Accounting from Hofstra University in 1991, and a Master of Business Administration in Finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York. |
Catherine Vaczy |
Ms. Catherine M. Vaczy is Vice President, General Counsel of NeoStem Inc., since April 2005. Ms. Vaczy is responsible for overseeing the legal affairs. From 1997 through 2003, Ms. Vaczy held senior positions at ImClone Systems Incorporated, a then publicly-traded company developing a portfolio of targeted biologic treatments to address the medical needs of patients with a variety of cancers, most recently as its Vice President, Legal and Associate General Counsel. While at ImClone, Ms. Vaczy served as a key advisor in the day-to-day operation of the company and helped forge a number of important strategic alliances, including a $1 billion co-development agreement for Erbitux®, the company's targeted therapy approved for the treatment of metastatic colorectal and head and neck cancers. From 1988 through 1996, Ms. Vaczy served as a corporate attorney advising clients in the life science industry at the New York City law firm of Ross & Hardies. Ms. Vaczy is Secretary and serves on the Board of Trustees of The Stem for Life Foundation. Ms. Vaczy received a Bachelor of Arts degree in 1983 from Boston College and a Juris Doctor |
Andrew Pecora |
Dr. Andrew L. Pecora is Chief Medical Officer, Director of NeoStem Inc. Mr. Berman's business career spans 35years of venture capital, management and merger & acquisitions experience. In the past 5 years, Mr. Berman has served as a director and/or officer of over a dozen public and private companies. From 2006-2011, he was Chairman of National Investment Managers (OTC: NIVM.OB), a company with $12 billion in pension administration assets. In 2012, he became vice chairman of Energy Smart Resources, Inc., a privately-held company. Mr. Berman is a director of two additional public companies: Advaxis, Inc. (OTC: NIVM.OB), and Lustros, Inc. (OTC: LSLD). From 1998-2000, he was employed by Internet Commerce Corporation (now Easylink Services (Nasadaq: ESIC)) as Chairman and CEO. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; helped create the battery company in the world by merging Prestolite, General Battery and Exide to form Exide Technologies (NASDAQ: XIDE); helped create what is now Soho (NYC) by developing five buildings; and advised on over $4 billion of M&A transactions. Mr. Berman is a past director of the Stern School of Business of NYU, where he received B.S. and M.B.A. degrees. Mr. Berman also has United States and foreign law degrees from Boston College and The Hague Academy of International Law, respectively. |
Eric Wei |
Mr. Eric H.C. Wei is Director of Neostem Inc., since October 2009. From July 2006 to Mark 2007, Mr. Wei served as a director of CBH . Eric H.C. Wei is one of the founders and the Managing Partner of RimAsia Capital Partners, L.P. a private equity firm focused on the pan-Asian mid-market sector and a greater-than-5% stockholder of NeoStem. Prior to establishing RimAsia in January of 2005, Mr. Wei was a managing director of Gilbert Global Equity Partners, a US$1.2 billion global private equity fund; a founding partner of Crimson Asia Capital Partners, a US$435 million Asian private equity program; a founder and investment committee member of the US$800 million Asian Infrastructure Fund, and an investor and director of The Asian MBO Fund. Mr. Wei has also previously been an investment banker with over 10 years of experience at Peregrine Capital, Prudential Securities, Lazard Freres and Citibank. Mr. Wei received a Bachelor of Science degree in Math and Economics from Amherst College and a Master of Business Administration degree from the Wharton Graduate School of Management at the University of Pennsylvania. |
Richard Berman |
Mr. Richard L.Berman is an Independent Director of NeoStem Inc. Mr. Berman continues to serve as a member of the Audit Committee. Mr. Berman's business career spans over thirty-five years of venture capital, management and merger & acquisitions experience. In the past 5 years, Mr. Berman has served as a director and/or officer of over a dozen public and private companies. From 2006-2011, he was Chairman of National Investment Managers (OTC: NIVM.OB), a company with $12 billion in pension administration assets. In 2012, he became vice chairman of Energy Smart Resources, Inc., a privately-held company. Mr. Berman is currently a director of two additional public companies: Advaxis, Inc. (OTC: NIVM.OB), and Lustros, Inc. (OTC: LSLD). From 1998-2000, he was employed by Internet Commerce Corporation (now Easylink Services (Nasadaq: ESIC)) as Chairman and CEO. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; helped create the battery company in the world by merging Prestolite, General Battery and Exide to form Exide Technologies (NASDAQ: XIDE); helped create what is now Soho (NYC) by developing five buildings; and advised on over $4 billion of M&A transactions. Mr. Berman is a past director of the Stern School of Business of NYU, where he received B.S. and M.B.A. degrees. Mr. Berman has United States and foreign law degrees from Boston College and The Hague Academy of International Law, respectively. |
Drew Bernstein |
Mr. Drew Bernstein is an Independent Director of NeoStem Inc. He was appointed to Board of Directors on June 9, 2009. Mr. Bernstein co-founded Bernstein & Pinchuk LLP (B&P) in 1983 (now the managing member of Marcum Bernstein & Pinchuk (MarcumBP), a PCAOB-registered accounting firm headquartered in New York). His early recognition of the global marketplace and his work in China resulted in the rapid expansion of the firm's services to the PRC where he established associate offices to better serve client needs. In addition, his diverse experience in retail, manufacturing, hospitality, professional practices and real estate contributed to the expansion of the firm's client base abroad. Mr. Bernstein provides business advisory and specialized auditing and accounting services to public and non-public companies throughout the United States, China, Europe and Africa. Mr. Bernstein received his BS degree from the University of Maryland Business School, is licensed in the State of New York, Connecticut, California, Texas and Maryland and is a member of the AICPA, the NYSSCPA and the NSA. Mr. Bernstein is a director (and the chairman of the audit committee) for Orient Paper, Inc. (AMEX: ONP), a holding company for a producer and distributor of paper products in China. |
Martyn Greenacre |
Mr. Martyn D. Greenacre is an Independent Director of NeoStem Inc., since December 8, 2011. Mr. Greenacre has served as Chairman of Life Mist Technologies, Inc. a privately-held fire suppression equipment company, since 2002. He previously was Chairman of the Board of BMP Sunstone Corporation, which was acquired by Sanofi-Aventis in February 2011. Mr. Greenacre also served as a director of Cephalon Inc., a biopharmaceutical company that was acquired by Teva Pharmaceutical Industries in October 2011, and Orchestra Therapeutics, an immuno-pharmaceutical company. He currently has the role of Chairman of the Board of Acusphere, Inc., a drug delivery company, and sits on the board of Curis, Inc., a biotechnology company. From 1997 to 2001, Mr. Greenacre served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company, where he helped raise more than $50 million in equity and partnership financing and formed three development partnerships with pharmaceutical companies. From 1993 to 1997, Mr. Greenacre served as President and Chief Executive Officer of Zynaxis Inc., a biopharmaceutical company, where he was responsible for a critical acquisition, divesting a non-performing business and negotiating a strategic merger. From 1989 to 1992, Mr. Greenacre was Chairman, Europe, SmithKline Beecham Pharmaceutical Company. He joined SmithKline & French in 1973, where he held positions of responsibility in its European organization. Mr. Greenacre received a B.A. from Harvard College and an MBA from Harvard Business School. |
Steven Myers |
Mr. Steven S. Myers is an Independent Director of NeoStem Inc., since November 2006. Mr. Myers is the founder, and until his retirement in March 2007 was the Chairman and CEO, of SM&A (Nasdaq:WINS), the world’s provider of Competition Management Services. SM&A helps businesses win structured competitive procurements and design transitions from proposals to programs. Since 1982, SM&A has managed over 1,000 proposals worth more than $340 billion for its clients. SM&A routinely supports clients such as Boeing, Lockheed Martin, Accenture, Raytheon, Northrop Grumman, Motorola, and other Fortune 500 companies. SM&A was publicly traded until 2008. Mr. Myers graduated from Stanford University with a B.S. in Mathematics and had a career in the aerospace and defense sector supporting Department of Defense and NASA programs before founding SM&A. He has a technical background in systems engineering and program management. Mr. Myers is founder, President and CEO of Dolphin Capital Holdings, Inc, which owns, operates and leases business jet aircraft and does private equity investing in innovative enterprises. A serial entrepreneur, Mr. Myers has spearheaded a number of business innovations in aerospace & defense and in business aviation. He is a accomplished aviator. |
Stephen Potter |
Mr. Stephen W. Potter is an Independent Director of NeoStem, Inc., since February 11, 2013. During 2011 and 2012, Mr. Potter served as Senior Vice President of Operations and Corporate Development for Osiris Therapeutics, Inc. During his tenure at Osiris, he worked as a member of the senior leadership that achieved approval of the first-ever stem cell drug therapy, Prochymal®. He was responsible for the launch and overall management of the Bio-Surgery business unit as well as operational oversight for multiple functional areas including manufacturing, human resources, IT, legal, and business development. Prior to his tenure at Osiris, from 2006 through 2010, Mr. Potter served as Senior Vice President of Corporate and Business Development at Genzyme Corporation and as Vice President of Corporate and Business Development from 2000 through 2006. Over his ten years at Genzyme, he was the senior leader for its global corporate and business development team that provided strategic and transaction support, including support for many of Genyzme's cell therapy opportunities. Mr. Potter has held positions at DuPont Pharmaceuticals, E.I. Dupont de Nemours and Company, Inc., and Booz Allen & Hamilton. Mr. Potter earned a B.S. from University of Massachusetts and an MBA from Harvard Business School. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Robin Smith |
1,643,400 |
Lawrence May |
567,830 |
Robert Preti |
407,458 |
Joseph Talamo |
-- |
Catherine Vaczy |
403,070 |
Andrew Pecora |
862,972 |
Eric Wei |
-- |
Richard Berman |
-- |
Drew Bernstein |
-- |
Martyn Greenacre |
-- |
Steven Myers |
-- |
Stephen Potter |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Robin Smith |
0 | 0 |
Lawrence May |
0 | 0 |
Robert Preti |
0 | 0 |
Joseph Talamo |
0 | 0 |
Catherine Vaczy |
1,100,000 | 19,000 |
Andrew Pecora |
0 | 0 |
Eric Wei |
0 | 0 |
Richard Berman |
0 | 0 |
Drew Bernstein |
0 | 0 |
Martyn Greenacre |
0 | 0 |
Steven Myers |
0 | 0 |
Stephen Potter |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PECORA ANDREW L |
6,547 | $0.54 |
PECORA ANDREW L |
5,612 | $0.63 |
PECORA ANDREW L |
5,199 | $0.68 |
PECORA ANDREW L |
5,124 | $0.69 |
PECORA ANDREW L |
5,524 | $0.64 |
SMITH ROBIN L |
100,000 | $0.53 |
PECORA ANDREW L |
5,893 | $0.60 |
POTTER STEPHEN W |
60,000 | $0.00 |
PECORA ANDREW L |
5,524 | $0.64 |
PECORA ANDREW L |
5,796 | $0.61 |
PECORA ANDREW L |
5,703 | $0.62 |
RIMASIA CAPITAL PARTNERS L P |
120,000 | $0.00 |
WEI ERIC H C |
120,000 | $0.00 |
WEI ERIC H C |
120,000 | $0.00 |
GREENACRE MARTYN D |
120,000 | $0.00 |
BERMAN RICHARD J |
146,923 | $0.00 |
MYERS STEVEN S |
170,000 | $0.00 |
PECORA ANDREW L |
5,703 | $0.61 |
PRETI ROBERT A |
5,998 | $0.60 |
BERMAN RICHARD J |
96,577 | $0.59 |
BERMAN RICHARD J |
50,000 | $0.59 |
BERMAN RICHARD J |
2,729 | $0.61 |
PECORA ANDREW L |
7,226 | $0.61 |
PECORA ANDREW L |
6,887 | $0.64 |
PECORA ANDREW L |
4,786 | $0.71 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
